Transient perforating folliculitis induced by sorafenib

M. Minami‐Hori,A. Ishida‐Yamamoto,S. Komatsu,Hajime Iiduka

DOI: https://doi.org/10.1111/j.1346-8138.2010.00885.x

2010-09-01

Abstract:Figure 1. Isolated, dark-red papules with central coneshaped keratotic plugging surrounded by erythema. Dear Editor, Sorafenib is an oral multikinase inhibitor originally developed as a Raf-1 kinase inhibiting agent, but has been demonstrated to inhibit other kinases such as vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, plateletderived growth factor receptor-b, and FLT3, as well. Cutaneous side-effects (including hand–foot syndrome, facial erythema, alopecia, xerosis, pruritus and subungual splinter hemorrhages) are frequently associated with sorafenib. Rarely, the drug induces perforating folliculitis (PF), keratosis pilaris-like eruption and follicular hyperplasia. Herein, we present a case of PF associated with sorafenib. To our knowledge, this is the first report of sorafenib-associated PF in Japan. A 77-year-old Japanese man was treated with sorafenib (two doses of 400 mg ⁄day) for metastatic renal cell carcinoma. Two weeks after the onset of the therapy, he noticed hair loss, which was followed by typical hand–foot syndrome with symmetrical red palms and soles and patchy hyperkeratosis on plantar pressure areas. Sorafenib was continued without lowering the dose and 7 weeks after the beginning of the therapy asymptomatic, solitary dark-red papules of up to 6 mm surrounded by erythema developed on the extensor side of the lower extremities, on buttocks and lumbar area (Fig. 1). Each papule contained a central cone-shaped keratotic plug. Histopathological examination disclosed prominent keratotic plugging, and dilated follicular infundibula filled with compact parakeratotic cornified cells, an example of which can be seen in Figure 2a. Neutrophils were infiltrating into the cornified cells. Upper follicular epithelial cells showed marked vacuolization (Fig. 2b) and dyskeratosis. Perifollicular lymphocytic infiltration and vascular proliferation were also noticed. The patient was diagnosed with PF associated with sorafenib. Although topical corticosteroid therapy